⚫ 公司对外许可收入增厚业绩，考虑到创新药出海有望持续，假设未来对外许可收入 稳定增长，故上调 2025-2027 年 EPS 为 1.19、1.36、1.54 元（原预测值分别为 1.06、1.17、1.42 元）。根据 PE 估值法及可比公司估值水平，给予公司 2025 年 62 倍市盈率，对应目标价为 84.32 元，维持"买入"评级。 风险提示 ⚫ 创新药研发不及预期的风险，创新药销售不及预期的风险，仿制药进入集采的风 险。 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 22,820 | 27,985 | 31,684 | 35,553 | 40,900 | | 同比增长 (%) | 7.3% | 22.6% | 13.2% | 12.2% | 15.0% | | 营业利润(百万元) | 4,910 | 7,491 | 9,088 | 10,355 | 11,738 | | 同比增长 (%) | 19.4% | 52.6% | 21.3% ...

Market Performance - On August 27, 2025, the North Exchange 50 index decreased by 2.60%, closing at 1550.44 points[3] - The overall trading volume on the North Exchange was 32.872 billion CNY, with a turnover rate of 5.59%[3] - Compared to the previous week, the average daily trading volume decreased from 41.701 billion CNY[3] Index Comparison - The Shanghai Composite Index closed at 3800.35 points, down by 1.76%[3] - The CSI 300 index closed at 4386.13 points, down by 1.49%[3] - The STAR 50 index increased slightly by 0.13%, closing at 1272.56 points[3] Sector Performance - Only the communication sector saw an increase of 0.7%, while the largest declines were in construction materials (-3.9%), beauty care (-3.9%), textiles and apparel (-3.8%), and basic chemicals (-3.7%)[3] - Among 273 listed companies, 34 saw an increase, 1 remained flat, and 238 experienced a decline[3] Stock Highlights - The top gainers included *ST Guandao (+30.00%), *ST Yunchuang (+17.10%), and Digital Human (+12.84%)[3] - The largest declines were seen in Xinzhi Biological (-9.92%), Tianrun Technology (-8.28%), and Hengtou Kaiyuan (-7.81%)[3] Valuation Metrics - The overall valuation of the North Exchange is at a P/E ratio of 53.90 times, which is higher than the ChiNext's 41.39 times[3] - The highest sector P/E ratio is in electronics at 259.3 times, followed by computers at 155.4 times[3] Risk Factors - Risks include lower-than-expected policy support, insufficient technological innovation, intensified market competition, and market volatility[3]

Investment Rating - The report maintains a "Buy" rating for the company [5][8] Core Views - The company's performance is in line with expectations, with a focus on innovation-driven growth [2][12] - The company achieved a revenue of 4.29 billion yuan in the first half of 2025, a year-on-year decrease of 1.9%, while the pharmaceutical industrial segment showed resilience with a revenue of 3.88 billion yuan, down 0.5% year-on-year [12] - The management efficiency is expected to improve following the completion of the acquisition by China Resources Sanjiu, which is anticipated to enhance long-term growth [12] - The company is accelerating its R&D pipeline with 83 projects in progress, focusing on innovative products in key therapeutic areas [12] Financial Summary - The company forecasts earnings per share (EPS) of 0.75, 0.89, and 0.95 yuan for 2025, 2026, and 2027 respectively [5] - Projected revenues for 2025, 2026, and 2027 are 9.069 billion, 9.723 billion, and 10.248 billion yuan, reflecting growth rates of 6.7%, 7.2%, and 5.4% respectively [7][14] - The net profit attributable to the parent company is expected to be 1.124 billion, 1.325 billion, and 1.423 billion yuan for 2025, 2026, and 2027, with year-on-year growth rates of 17.6%, 17.9%, and 7.4% respectively [7][14] - The company's gross margin is projected to remain stable around 66.5% to 66.7% over the next few years [7][14]

经本公司申请，本公司将于2025年8月28日在中国证券登记结算有限责任公司上海分公司注销2025年第 一次股份回购方案项下回购的全部1186.08万股A股，并及时办理变更登记手续等相关事宜。 智通财经APP讯，药明康德(02359)发布公告，2025年8月26日，本公司实施完毕2025年第一次股份回购 方案，已通过集中竞价交易方式回购A股股份共1186.08万股，占本公司截至本公告日期已发行总股本的 0.40%。2025年第一次股份回购最高价格为每股A股人民币102.23元，2025年第一次股份回购最低价格 为每股A股人民币65.53元，2025年第一次股份回购均价为每股A股人民币84.31元。使用资金总额为人民 币10亿元(不含交易费用)。 ...

以最新收盘价计算，A股平均股价为13.21元，其中股价超过100元的有138只，相比上一个交易日减少3 只。 市场表现方面，收盘股价超百元股中，今日平均下跌0.18%，跑赢沪指1.58个百分点。今日上涨的有51 只，涨停的有瑞芯微、开普云等，下跌的有87只，跌幅居前的有热景生物、广生堂等。 追溯发现，最新百元股近一个月平均上涨25.50%，其间沪指上涨5.75%，涨幅居前的有东芯股份、思泉 新材、浙海德曼等，涨幅分别为171.35%、133.12%、121.91%，今年以来平均涨幅为72.33%，强于沪指 58.94%，累计涨幅居前的有胜宏科技、北方长龙、浙海德曼等，涨幅分别为416.63%、368.65%、 322.03%。 今日有1只股收盘价首次突破百元大关，开普云最新收盘价113.70元，上涨20.00%，全天换手率0.08%， 成交额6.00亿元，全天主力资金净流入1933.92万元。 最新百元股中，以申万一级行业分类，较为集中的行业有电子、计算机、医药生物等，其中，电子行业 有44只股上榜，占百元股总数的比例为31.88%；有19只股来自计算机行业，占比13.77%；17只股来自 医药生物行业，占比 ...

以最新收盘价计算，科创板平均股价为38.96元，其中股价超100元的有65只，股价最高的是寒武纪。 资金流向方面，科创板百元股今日主力资金合计净流出1.51亿元，净流入资金居前的有翱捷科技、芯原 股份、中芯国际等，净流入资金分别为26454.83万元、24854.06万元、22807.63万元；净流出资金居前 的有海光信息、东芯股份、中微公司等，净流出资金分别为64721.50万元、32733.08万元、21237.93万 元。 融资融券方面，百元股最新（8月26日）融资余额合计694.05亿元，融资余额居前的有中芯国际、寒武 纪、海光信息等，最新融资余额分别为107.31亿元、88.52亿元、65.85亿元。最新融券余额合计为3.68亿 元，融券余额居前的有寒武纪、海光信息、中芯国际等，最新融券余额分别为0.49亿元、0.40亿元、 0.31亿元。（数据宝） 科创板百元股一览 | 代码 | 简称 | 最新收盘价（元） | 今日涨跌（%） | 换手率（%） | 行业 | | --- | --- | --- | --- | --- | --- | | 688256 | 寒武纪 | 1372.10 | 3.24 ...

Summary of Key Points Core Viewpoint - A total of 628 stocks reported their latest shareholder numbers as of August 20, with 326 stocks showing a decline in shareholder numbers compared to the previous period, indicating a trend of decreasing investor interest in certain stocks [1][3]. Group 1: Shareholder Changes - Among the 628 stocks, 34 stocks experienced a decline in shareholder numbers exceeding 10% [3]. - The stock with the largest decline in shareholder numbers was Huakang Clean, which saw a decrease of 27.60% to 10,900 shareholders [3][4]. - Other notable declines included Sheyan Institute with a 24.78% drop and Jiangshun Technology with a 24.66% drop [3][4]. Group 2: Stock Performance - The average increase for concentrated stocks from August 1 to August 10 was 6.34%, slightly underperforming the Shanghai Composite Index, which rose by 6.36% [2]. - Among the stocks with a decline in shareholder numbers, Anpeilong had the highest increase of 51.31% since August 1 [2][3]. - Stocks such as Dongtianwei and Hangzhou High-tech also showed significant gains of 38.18% and 33.92%, respectively [2][3]. Group 3: Industry Insights - The concentrated stocks are primarily found in the machinery, basic chemicals, and pharmaceutical industries, with 45, 34, and 27 stocks respectively [3]. - The performance of concentrated stocks from August 11 onwards averaged an increase of 2.15%, with leading stocks including Boyuan Co., Beifang Rare Earth, and *ST Jinglun [3][4]. Group 4: Financial Performance - Among the concentrated stocks, 179 have reported their semi-annual results, with Fuji Lai showing the highest net profit growth of 12,430.96% [4]. - Companies like Yalian Machinery and Donghua Technology reported net profit growths of 20.57% and 14.64%, respectively [4].

Group 1 - A total of 356 buy ratings were issued by institutions today, covering 267 stocks, with China Ping An receiving the highest attention with 6 buy ratings [1] - Among the stocks rated, 100 provided future target prices, with 5 stocks showing an upside potential exceeding 50%, led by Longxin General with a potential increase of 71.48% [1] - 12 stocks received initial attention from institutions today, including Amway and Baofeng Energy, while ratings were upgraded for Guangdong Hongda and Nairui Radar [1] Group 2 - The average decline for stocks with buy ratings was 1.50%, outperforming the Shanghai Composite Index, with notable gainers including Anli Shares and Zhongke Chuangda, which rose by 13.05% and 11.69% respectively [2] - Among the rated stocks, 263 have reported their first-half earnings, with New Special Electric achieving a net profit of 532.87 million yuan, a staggering year-on-year increase of 49,775.01% [2] - The pharmaceutical and biotechnology sector was the most favored, with 30 stocks like Anke Bio and Aier Eye Hospital making the buy rating list, followed by machinery and electronics with 27 and 21 stocks respectively [2]

8月27日，沪指下跌1.76%，深成指下跌1.43%，创业板指下跌0.69%，沪深300指数下跌1.49%。可交易 A股中，上涨的有633只，占比11.69%，下跌的4764只。 资金面上，今日主力资金全天净流出1297.50亿元，已连续3个交易日资金呈净流出状态。其中，创业板 主力资金净流出375.89亿元；科创板主力资金净流出51.65亿元；沪深300成份股主力资金净流出382.09 亿元。 分行业来看，申万所属的一级行业中，今日上涨的有1个，涨幅居前的行业为通信，涨幅为1.66%。跌 幅居前的行业为美容护理、房地产，跌幅为3.86%、3.51%。 行业资金流向方面，今日所属的申万行业主力资金均呈净流出状态，计算机行业主力资金净流出规模居 首，今日下跌1.38%，全天净流出资金163.10亿元，其次是医药生物行业，今日跌幅为2.73%，净流出资 金为123.25亿元，净流出资金较多的还有电子、汽车、机械设备等行业。 今日各行业资金流向 | 行业 | 日涨跌幅（%） | 资金流向（亿元） | 行业 | 日涨跌幅（%） | 资金流向（亿元） | | --- | --- | --- | --- | --- | ...

Market Overview - The Shanghai Composite Index fell by 1.76% on August 27, with only one industry, communication, showing an increase of 1.66%. The beauty care and real estate sectors experienced the largest declines, down 3.86% and 3.51% respectively. The pharmaceutical and biotechnology sector also saw a decrease of 2.73% [1]. Capital Flow Analysis - The main capital outflow from both markets totaled 129.75 billion yuan, with all sectors under the Shenwan classification experiencing net outflows. The computer industry led with a net outflow of 16.31 billion yuan, followed by the pharmaceutical and biotechnology sector with a net outflow of 12.33 billion yuan. Other sectors with significant outflows included electronics, automotive, and machinery equipment [1]. Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector had 474 stocks, with 36 gaining and 438 losing value. Five stocks hit the daily limit up, while one stock hit the limit down. The sector saw a net outflow of 12.33 billion yuan, with 114 stocks experiencing net inflows, and 28 stocks seeing outflows exceeding 100 million yuan [2]. Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jimin Health: +9.97% with a net inflow of 118.04 million yuan - Nanxin Pharmaceutical: +20.00% with a net inflow of 109.05 million yuan - BGI Genomics: +0.09% with a net inflow of 106.94 million yuan [2]. Major Outflows in Pharmaceutical Sector - The stocks with the largest net outflows included: - Hengrui Medicine: -3.45% with a net outflow of 901.64 million yuan - WuXi AppTec: -1.45% with a net outflow of 482.18 million yuan - Guangsheng Tang: -10.32% with a net outflow of 378.57 million yuan [3].